Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Net Margin · Q2 FY2026 · quarter ended Mar 2026
Net margin widens to -76.3%
Net margin was -76.3% in Q2 FY2026, up 75.4 pp from a year earlier. On a trailing-twelve-month basis it was -89.6%, up 60.0 pp year over year. Over 3 fiscal years it widened by 16.0 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of -103.2% for the fiscal year ending Sep 2026, up from -125.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -76.3%-12.2 pp QoQ
- Last fiscal yearSep 2025
- -125.4%+46.2 pp YoY
- LTMMar 2026
- -89.6%+60.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +75.4 pp | +11.1 pp | -64.3 pp |
| 1 year | +46.2 pp | +22.2 pp | -24.0 pp |
| 3 years | +16.0 pp | -7.4 pp | -23.4 pp |
| 5 years | +55.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -125.4%
- Year-over-year change
- +46.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | -125.4% | +46.2pp |
| FY2024 | 2024-09-30 | -171.6% | -2.6pp |
| FY2023 | 2023-09-30 | -169.0% | -27.6pp |
| FY2022 | 2022-09-30 | -141.3% | -59.9pp |
| FY2021 | 2021-09-30 | -81.4% | — |
Net Margin vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's LTM Mar 2026 net margin of -89.6% is the 2nd highest of the 8 companies compared; the peer median is -465.3%.
- Its year-over-year change of +60.0 pp is the 5th highest of 6, against a peer median of +115.2 pp.
- Over three fiscal years its change of +16.0 pp compares with a peer median of -183.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -9.0% | +115.2 pp | — | |
| LTM Mar 2026 | -89.6% | +60.0 pp | +16.0 pp | |
| LTM Mar 2026 | -266.9% | +75.4 pp | +325.9 pp | |
| LTM Mar 2026 | -319.6% | -193.1 pp | -183.1 pp | |
| LTM Mar 2026 | -465.3% | +1360.8 pp | — | |
| LTM Mar 2026 | -589.8% | — | — | |
| LTM Mar 2026 | -1189.1% | +301.7 pp | -609.6 pp | |
| LTM Mar 2026 | -36891.1% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ENTA) | -465.3% | +115.2 pp | -183.1 pp | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 97.07M | 86.16M | 79.2M | 67.64M | 65.32M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.59M |
| Gross Profit | 97.07M | 86.16M | 79.2M | 67.64M | 60.74M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| Research & Development | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M |
| Selling, General & Admin | 32.54M | 45.48M | 52.89M | 57.85M | 43.93M |
| Operating Expenses | 206.65M | 210M | 216.41M | 189.33M | 146.09M |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| EBITDA | (104.25M) | (119.22M) | (123.48M) | (104.51M) | (70.78M) |
| EBITDA Margin | -107.4% | -138.4% | -155.9% | -154.5% | -108.4% |
| Operating Income | (109.57M) | (123.84M) | (137.21M) | (121.69M) | (85.35M) |
| Operating Margin | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Interest Income | 2.02M | 1.57M | 11.36M | 14.77M | 9.48M |
| Interest Expense | 0 | 0 | 5.15M | 10.94M | 7.68M |
| Other Income / Expenses | 1.99M | 1.66M | 6.21M | 3.9M | 1.8M |
| Income Before Tax | (107.58M) | (122.19M) | (131M) | (117.79M) | (83.55M) |
| Pre-Tax Margin | -110.8% | -141.8% | -165.4% | -174.2% | -127.9% |
| Income Tax Expense | (28.58M) | (433K) | 2.82M | (1.74M) | (1.66M) |
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Net Margin | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
| EPS (Basic) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| EPS (Diluted) | (3.92) | (5.91) | (6.38) | (5.48) | (3.84) |
| Weighted Avg Shares | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
| Weighted Avg Shares (Diluted) | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.